The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform
Klaas Heinemann - One of the best experts on this subject based on the ideXlab platform.
-
Drospirenone Plus Estradiol and the risk of serious cardiovascular events in postmenopausal women
Climacteric, 2016Co-Authors: Jurgen Dinger, Kristina Bardenheuer, Klaas HeinemannAbstract:AbstractObjectives: To compare incidence rates of serious cardiovascular events, particularly arterial thromboembolic events (ATE), in users of hormone replacement therapy (HRT), particularly oral continuous combined preparations.Methods: Prospective, controlled cohort study with four arms: women using (1) Drospirenone (DRSP)/Estradiol, (2) other oral continuous combined HRT (HRTcc), (3) all other oral HRTs, and (4) non-oral HRT. The study population consisted of women aged 40+ years in seven European countries who were new users of HRT at the time of inclusion. All patient-reported outcomes of interest were validated by the treating physicians. A multifaceted, four-level follow-up procedure ensured low loss to follow-up rates. The final analysis is based on Cox regression models comparing the cohorts.Results: In total, 30 597 women were recruited by 1052 study centers. Follow-up reflects 101 715 woman-years of observation. Loss to follow-up was about 2.8%. Risk estimates for general serious adverse event...
Jurgen Dinger - One of the best experts on this subject based on the ideXlab platform.
-
Drospirenone Plus Estradiol and the risk of serious cardiovascular events in postmenopausal women
Climacteric, 2016Co-Authors: Jurgen Dinger, Kristina Bardenheuer, Klaas HeinemannAbstract:AbstractObjectives: To compare incidence rates of serious cardiovascular events, particularly arterial thromboembolic events (ATE), in users of hormone replacement therapy (HRT), particularly oral continuous combined preparations.Methods: Prospective, controlled cohort study with four arms: women using (1) Drospirenone (DRSP)/Estradiol, (2) other oral continuous combined HRT (HRTcc), (3) all other oral HRTs, and (4) non-oral HRT. The study population consisted of women aged 40+ years in seven European countries who were new users of HRT at the time of inclusion. All patient-reported outcomes of interest were validated by the treating physicians. A multifaceted, four-level follow-up procedure ensured low loss to follow-up rates. The final analysis is based on Cox regression models comparing the cohorts.Results: In total, 30 597 women were recruited by 1052 study centers. Follow-up reflects 101 715 woman-years of observation. Loss to follow-up was about 2.8%. Risk estimates for general serious adverse event...
Kristina Bardenheuer - One of the best experts on this subject based on the ideXlab platform.
-
Drospirenone Plus Estradiol and the risk of serious cardiovascular events in postmenopausal women
Climacteric, 2016Co-Authors: Jurgen Dinger, Kristina Bardenheuer, Klaas HeinemannAbstract:AbstractObjectives: To compare incidence rates of serious cardiovascular events, particularly arterial thromboembolic events (ATE), in users of hormone replacement therapy (HRT), particularly oral continuous combined preparations.Methods: Prospective, controlled cohort study with four arms: women using (1) Drospirenone (DRSP)/Estradiol, (2) other oral continuous combined HRT (HRTcc), (3) all other oral HRTs, and (4) non-oral HRT. The study population consisted of women aged 40+ years in seven European countries who were new users of HRT at the time of inclusion. All patient-reported outcomes of interest were validated by the treating physicians. A multifaceted, four-level follow-up procedure ensured low loss to follow-up rates. The final analysis is based on Cox regression models comparing the cohorts.Results: In total, 30 597 women were recruited by 1052 study centers. Follow-up reflects 101 715 woman-years of observation. Loss to follow-up was about 2.8%. Risk estimates for general serious adverse event...
